Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms
Daniele Vanni,
Oscar Borsani,
Yasuhito Nannya,
Emanuela Sant'Antonio,
Chiara Trotti,
Ilaria Carola Casetti,
Daniela Pietra,
Anna Gallì,
Silvia Zibellini,
Virginia Valeria Ferretti,
Luca Malcovati,
Seishi Ogawa,
Luca Arcaini,
Elisa Rumi
Affiliations
Daniele Vanni
Department of Molecular Medicine University of Pavia Pavia Italy
Oscar Borsani
Department of Molecular Medicine University of Pavia Pavia Italy
Yasuhito Nannya
Department of Pathology and Tumor Biology Kyoto University Kyoto Japan
Emanuela Sant'Antonio
Division of Haematology Azienda USL Toscana Nord Ovest Lucca Italy
Chiara Trotti
Department of Molecular Medicine University of Pavia Pavia Italy
Ilaria Carola Casetti
Department of Molecular Medicine University of Pavia Pavia Italy
Daniela Pietra
Division of Haematology Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo Pavia Italy
Anna Gallì
Division of Haematology Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo Pavia Italy
Silvia Zibellini
Division of Haematology Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo Pavia Italy
Virginia Valeria Ferretti
Service of Clinical Epidemiology and Biostatistics Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo Pavia Italy
Luca Malcovati
Department of Molecular Medicine University of Pavia Pavia Italy
Seishi Ogawa
Department of Pathology and Tumor Biology Kyoto University Kyoto Japan
Luca Arcaini
Department of Molecular Medicine University of Pavia Pavia Italy
Elisa Rumi
Department of Molecular Medicine University of Pavia Pavia Italy
Abstract In a cohort of 3131 patients with myeloproliferative neoplasms (MPNs), we identified 200 patients (6.4%) who reported a second case of haematological malignancies (HM) in first‐ or second‐degree relatives. The occurrence of a second HM in the family was not influenced by MPN subtype, sex or driver mutation, while it was associated with age at MPN diagnosis: 8.5% of patients diagnosed with MPN younger than 45 years had a second relative affected with HM compared to 5.5% of those diagnosed at the age of 45 years or older (p = 0.003), thus suggesting a genetic predisposition to HM with early onset.
